Top Page
Alvotech
(NASDAQ:ALVO)
Alvotech (ALVO) vs. SPDR S&P 500 ETF (SPY)
Alvotech Business Overview & Revenue Model
Alvotech Earnings Call Summary
Alvotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 571.16M | 489.68M | 91.43M | 83.03M | 36.77M | 66.62M |
| Gross Profit | 316.53M | 304.37M | -69.42M | 18.93M | 36.77M | 66.62M |
| EBITDA | 72.66M | -32.27M | -493.67M | -439.80M | -18.03M | -177.88M |
| Net Income | 69.53M | -231.86M | -551.73M | -513.58M | -101.50M | -170.04M |
Balance Sheet | ||||||
| Total Assets | 1.41B | 1.22B | 950.09M | 828.44M | 597.98M | 474.42M |
| Cash, Cash Equivalents and Short-Term Investments | 42.85M | 51.43M | 11.16M | 66.43M | 17.56M | 31.69M |
| Total Debt | 1.28B | 1.19B | 1.08B | 805.10M | 523.05M | 676.85M |
| Total Liabilities | 1.59B | 1.63B | 1.88B | 1.39B | 733.59M | 1.34B |
| Stockholders Equity | -176.76M | -412.77M | -932.49M | -564.42M | -135.61M | -867.24M |
Cash Flow | ||||||
| Free Cash Flow | -113.45M | -293.84M | -358.66M | -361.39M | -268.80M | -86.28M |
| Operating Cash Flow | -26.49M | -236.84M | -312.19M | -312.39M | -228.17M | -74.30M |
| Investing Cash Flow | -119.50M | -18.87M | -46.34M | -63.54M | -40.63M | -16.90M |
| Financing Cash Flow | 68.36M | 297.31M | 301.32M | 424.91M | 254.83M | 55.40M |
Alvotech Technical Analysis
Alvotech Risk Analysis
Alvotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.91B | 52.31 | 7.83% | ― | 48.87% | ― | |
58 Neutral | $4.17B | 928.87 | ― | ― | 9.50% | ― | |
55 Neutral | $2.97B | -147.48 | -1.86% | ― | 4.54% | -130.59% | |
52 Neutral | $2.62B | 5.71 | 47.54% | ― | -1.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.05B | -40.27 | -0.65% | 8.48% | -2.55% | 66.00% | |
42 Neutral | $1.49B | 21.49 | ― | ― | 55.38% | ― |
Alvotech Corporate Events
On January 6, 2026, Alvotech announced that ATP Holdings ehf., a company closely associated with CEO and chairman Róbert Wessman, had reported to the Luxembourg financial regulator the acquisition of 4,812,257 Alvotech shares on December 17, 2025, and the sale of 2,110,640 shares on December 19, 2025, both at a price of SEK 44.06 per share. The disclosure, formalized in a Form 6-K filed on January 7, 2026, corrects an earlier same-day announcement that had mistakenly characterized the December 19, 2025 transaction as an acquisition rather than a sale, underscoring the company’s obligation to provide accurate reporting of insider-related dealings to both Luxembourg and U.S. market participants.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On January 6, 2026, Alvotech disclosed insider-related share purchases reported to Luxembourg’s financial regulator, indicating increased ownership by entities closely associated with the company’s leadership. Alvogen Lux Holdings S.a.r.l., linked to Alvotech’s CEO and board members, acquired 7,007,321 Alvotech shares at SEK 44.06 per share in a transaction dated December 17, 2025, while ATP Holdings ehf. bought 4,812,257 shares on December 17, 2025, and an additional 2,110,640 shares on December 19, 2025, at the same price, signaling a significant vote of confidence from key stakeholders and potentially strengthening the company’s shareholder structure.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On January 6, 2026, Alvotech announced a planned senior leadership transition following a long-prepared CEO succession process, with founder and current CEO Róbert Wessman set to step down from the chief executive role at the end of the first quarter of 2026 while remaining in a full-time capacity as Executive Chairman. The company has appointed long-time collaborator and board member Lisa Graver, a veteran pharmaceuticals executive and former CEO of Alvogen, as the incoming Chief Executive Officer, with an immediate transition period to ensure operational continuity and a smooth handover; the move consolidates leadership in Iceland alongside Alvotech’s core operations and is positioned as a way to support the next phase of growth for its expanding biosimilar portfolio and global partnerships, while Wessman shifts his focus to strategy, business development, portfolio direction, capital markets and corporate governance.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On December 31, 2025, Alvotech announced it had secured a new USD 100 million senior term loan facility maturing in December 2027, replacing its previous working capital asset-based lending facility and providing full access to the funds throughout the term. Led by GoldenTree Asset Management and bearing a 12.5% cash interest rate with monthly payments, the financing is intended to reinforce liquidity and operational flexibility as Alvotech advances a 30-product biosimilar R&D pipeline, expands production capacity and funds four planned global product launches through 2026, complementing earlier refinancing steps and a recent USD 108 million senior unsecured convertible bond issue that collectively bolster the company’s capital structure and support its strategic growth plans.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On December 22, 2025, Alvotech reported that launches have begun across Europe for Gobivaz (golimumab), its biosimilar to Johnson & Johnson’s Simponi and the first Simponi biosimilar to reach any market globally. Commercialized exclusively in Europe by partner Advanz Pharma and backed in the UK by an NHS England tender award, Gobivaz is being introduced via prefilled syringe and autoinjector formats identical to the reference product, with availability in other EEA countries to roll out as national pricing and reimbursement decisions are completed; the product is manufactured at Alvotech’s Iceland facility and its approval followed extensive analytical, pre-clinical and clinical comparability studies, underscoring the company’s drive to expand access to lower-cost biologic treatments for immune-mediated inflammatory diseases.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On December 19, 2025, Alvotech reported that it and its U.S. commercial partner Teva Pharmaceuticals have reached a settlement and license agreement with Regeneron Pharmaceuticals covering AVT06, Alvotech’s proposed biosimilar to the eye drug Eylea (aflibercept), setting a licensed U.S. market entry date in the fourth quarter of 2026, or earlier under certain conditions, pending FDA approval. The deal, which follows AVT06 marketing approvals in the UK, Japan and the European Economic Area and positive 2024 phase 3 data in wet age-related macular degeneration, secures a clear U.S. launch pathway for Alvotech’s aflibercept biosimilar, strengthening its and Teva’s positioning in the high-value retinal disease market and potentially intensifying future price competition for stakeholders once the product can be introduced in the United States.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Alvotech successfully completed the placement of $108 million senior unsecured convertible bonds on December 17, 2025, in a highly oversubscribed offering scheduled to settle by December 22, 2025. This funding strengthens the company’s ability to scale manufacturing and support product launches, aligning with its goal to invest $250 million in R&D in 2026, including launching four new global biosimilars. The issuance reinforces the company’s market positioning and commitment to advancing access to affordable biologic treatments, while reflecting robust confidence from international professional investors.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 24, 2025, Alvotech announced that its biosimilar AVT03, equivalent to Prolia and Xgeva (denosumab), received approval for marketing in the European Economic Area. This approval is a significant milestone for Alvotech, enhancing its biosimilar portfolio and reinforcing its position as a key partner in European healthcare systems. The introduction of AVT03 is expected to broaden access to essential osteoporosis and oncology treatments, supporting sustainable healthcare budgets by offering cost-effective alternatives. The European denosumab market, valued at approximately $1.2 billion, will benefit from Alvotech’s partnerships with STADA and Dr. Reddy’s, who will commercialize AVT03 under different brand names in Europe.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 20, 2025, Alvotech, in partnership with Advanz Pharma, announced that their biosimilar product Gobivaz®, a version of Simponi® (golimumab), received marketing approval from the European Commission for use in the European Economic Area. This approval marks a significant milestone as Gobivaz® is the first biosimilar to Simponi® approved in Europe, enhancing Alvotech’s commercial presence in the region and expanding access to biologic medicines for immune-mediated diseases. The approval is based on comprehensive analytical and clinical data, further solidifying Alvotech’s position in the biosimilar market.
The most recent analyst rating on (ALVO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 12, 2025, Alvotech announced its financial results for the first nine months of 2025, reporting a 24% increase in total revenues to $420 million compared to the previous year. Despite a decrease in adjusted EBITDA by 21% due to increased R&D investments, the company revised its full-year revenue outlook to $570-$600 million, anticipating strong growth driven by new biosimilar approvals in Japan and Europe. Alvotech’s strategic focus on expanding its biosimilar portfolio and maintaining operational excellence positions it for continued growth, with significant product launches expected in Q4 2025 and beyond.
The most recent analyst rating on (ALVO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 10, 2025, Alvotech announced that the UK High Court ruled in its favor, rejecting an injunction request from Regeneron Pharmaceuticals and Bayer. This decision allows Alvotech to continue manufacturing its biosimilar to Eylea (AVT06) in the UK, paving the way for its commercial launch in the European Economic Area and other regions after the expiry of the Supplementary Protection Certificates for Eylea on November 23, 2025. The ruling supports Alvotech’s strategy to enhance access to biosimilars and strengthen its position in the global biosimilar market.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 6, 2025, Alvotech announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved its biosimilar to Simponi, named Gobivaz, for various immune-mediated diseases. The approval covers multiple presentations of Gobivaz, enhancing Alvotech’s market positioning by broadening access to biologic treatments in the UK. This development, in partnership with Advanz Pharma, underscores Alvotech’s capabilities in biosimilar development and manufacturing, potentially impacting stakeholders by increasing treatment availability for conditions like rheumatoid arthritis and ulcerative colitis.
The most recent analyst rating on (ALVO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On November 2, 2025, Alvotech announced that the U.S. FDA issued a complete response letter for its Biologics License Application for AVT05, a biosimilar candidate to Simponi®. The letter highlighted deficiencies in Alvotech’s Reykjavik facility, which must be resolved before approval. Despite the setback, the facility remains FDA-approved for current products. Alvotech has revised its 2025 financial outlook, anticipating lower revenues and adjusted EBITDA due to ongoing investments in facility improvements, which are expected to support future growth and product launches.
The most recent analyst rating on (ALVO) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
On October 22, 2025, Alvotech announced significant changes to its commercial team, with the departure of Anil Okay, the Chief Commercial Officer, who will become the CEO of Adalvo. Trisha Durant joins as Senior Vice President for Global Business Development and Commercial Operations, excluding North America, while Harshika Sarbajna and Agne Pasko take on key roles in North America and global business development, respectively. These leadership changes are expected to strengthen Alvotech’s commercial operations and strategic partnerships, enhancing its position in the biosimilar industry.
The most recent analyst rating on (ALVO) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.